IBDEI0RW ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13082,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,13082,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,13082,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,13083,0)
 ;;=E11.9^^53^585^21
 ;;^UTILITY(U,$J,358.3,13083,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13083,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,13083,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,13083,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,13084,0)
 ;;=E13.9^^53^585^22
 ;;^UTILITY(U,$J,358.3,13084,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13084,1,3,0)
 ;;=3^Diabetes Mellitus (Secondary) w/o Complications NEC
 ;;^UTILITY(U,$J,358.3,13084,1,4,0)
 ;;=4^E13.9
 ;;^UTILITY(U,$J,358.3,13084,2)
 ;;=^5002704
 ;;^UTILITY(U,$J,358.3,13085,0)
 ;;=E16.2^^53^585^29
 ;;^UTILITY(U,$J,358.3,13085,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13085,1,3,0)
 ;;=3^Hypoglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,13085,1,4,0)
 ;;=4^E16.2
 ;;^UTILITY(U,$J,358.3,13085,2)
 ;;=^5002708
 ;;^UTILITY(U,$J,358.3,13086,0)
 ;;=E20.0^^53^585^34
 ;;^UTILITY(U,$J,358.3,13086,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13086,1,3,0)
 ;;=3^Idiopathic Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,13086,1,4,0)
 ;;=4^E20.0
 ;;^UTILITY(U,$J,358.3,13086,2)
 ;;=^5002712
 ;;^UTILITY(U,$J,358.3,13087,0)
 ;;=E20.9^^53^585^30
 ;;^UTILITY(U,$J,358.3,13087,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13087,1,3,0)
 ;;=3^Hypoparathyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,13087,1,4,0)
 ;;=4^E20.9
 ;;^UTILITY(U,$J,358.3,13087,2)
 ;;=^5002714
 ;;^UTILITY(U,$J,358.3,13088,0)
 ;;=E23.0^^53^585^31
 ;;^UTILITY(U,$J,358.3,13088,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13088,1,3,0)
 ;;=3^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,13088,1,4,0)
 ;;=4^E23.0
 ;;^UTILITY(U,$J,358.3,13088,2)
 ;;=^60685
 ;;^UTILITY(U,$J,358.3,13089,0)
 ;;=E27.1^^53^585^51
 ;;^UTILITY(U,$J,358.3,13089,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13089,1,3,0)
 ;;=3^Primary Adrenocortical Insufficiency
 ;;^UTILITY(U,$J,358.3,13089,1,4,0)
 ;;=4^E27.1
 ;;^UTILITY(U,$J,358.3,13089,2)
 ;;=^5002740
 ;;^UTILITY(U,$J,358.3,13090,0)
 ;;=E27.2^^53^585^1
 ;;^UTILITY(U,$J,358.3,13090,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13090,1,3,0)
 ;;=3^Addisonian Crisis
 ;;^UTILITY(U,$J,358.3,13090,1,4,0)
 ;;=4^E27.2
 ;;^UTILITY(U,$J,358.3,13090,2)
 ;;=^263725
 ;;^UTILITY(U,$J,358.3,13091,0)
 ;;=E27.3^^53^585^23
 ;;^UTILITY(U,$J,358.3,13091,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13091,1,3,0)
 ;;=3^Drug-induced Adrenocortical Insufficiency
 ;;^UTILITY(U,$J,358.3,13091,1,4,0)
 ;;=4^E27.3
 ;;^UTILITY(U,$J,358.3,13091,2)
 ;;=^5002741
 ;;^UTILITY(U,$J,358.3,13092,0)
 ;;=E29.1^^53^585^52
 ;;^UTILITY(U,$J,358.3,13092,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13092,1,3,0)
 ;;=3^Testicular Hypofunction
 ;;^UTILITY(U,$J,358.3,13092,1,4,0)
 ;;=4^E29.1
 ;;^UTILITY(U,$J,358.3,13092,2)
 ;;=^5002754
 ;;^UTILITY(U,$J,358.3,13093,0)
 ;;=E55.9^^53^585^59
 ;;^UTILITY(U,$J,358.3,13093,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13093,1,3,0)
 ;;=3^Vitamin D Deficiency,Unspec
 ;;^UTILITY(U,$J,358.3,13093,1,4,0)
 ;;=4^E55.9
 ;;^UTILITY(U,$J,358.3,13093,2)
 ;;=^5002799
 ;;^UTILITY(U,$J,358.3,13094,0)
 ;;=E66.01^^53^585^38
 ;;^UTILITY(U,$J,358.3,13094,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13094,1,3,0)
 ;;=3^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,13094,1,4,0)
 ;;=4^E66.01
 ;;^UTILITY(U,$J,358.3,13094,2)
 ;;=^5002826
 ;;^UTILITY(U,$J,358.3,13095,0)
 ;;=E66.8^^53^585^42
 ;;^UTILITY(U,$J,358.3,13095,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13095,1,3,0)
 ;;=3^Obesity NEC
 ;;^UTILITY(U,$J,358.3,13095,1,4,0)
 ;;=4^E66.8
